The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Shchukin I.A.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies
Koltsov I.A.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies
Fidler M.S.
Pirogov Russian National Research Medical University (Pirogov University)
Glukhareva A.P.
Pirogov Russian National Research Medical University (Pirogov University)
Neurocytoprotection advances in reperfusion therapy
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12‑2): 75‑88
Views: 463
Downloaded: 3
To cite this article:
Shchukin IA, Koltsov IA, Fidler MS, Glukhareva AP. Neurocytoprotection advances in reperfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry.
2024;124(12‑2):75‑88. (In Russ.)
https://doi.org/10.17116/jnevro202412412275
Acute stroke is the second leading cause of death and the third leading cause of disability in the world. Ischemic stroke (IS) the most common type of stroke. In acute cerebral ischemia, damage to the brain tissue is complex and includes blood-brain barrier (BBB) dysfunction, neuroinflammation, oxidative stress, activation of intracellular and extracellular signaling pathways, expression of neurotoxic agents, excitotoxicity, and apoptosis. In acute IS, reperfusion therapy (RT), is one of the most prominent treatment options. Most of the randomized clinical trials demonstrated the efficacy and safety of RT. The use of novel neuroimaging techniques (CT-perfusion and new MRI modalities) significantly expanded the RT selection criteria in patients with IS. One of the possible ways to further expand the RT is to combine it with neurocytoprotection. According to many researchers, this could potentially significantly improve the efficacy and safety of RT. This opinion is based on the concept of preserving brain tissue in the ischemic penumbra region. The aim of this review was to analyze the current trials of neurocytoprotection in combination with RT in IS patients.
Keywords:
Authors:
Shchukin I.A.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies
Koltsov I.A.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies
Fidler M.S.
Pirogov Russian National Research Medical University (Pirogov University)
Glukhareva A.P.
Pirogov Russian National Research Medical University (Pirogov University)
Received:
12.12.2024
Accepted:
13.12.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.